A Case of Bone, Lung, Pleural and Liver Metastases from Renal Cell Carcinoma Which Responded Remarkably Well to Zoledronic Acid Monotherapy
Open Access
- 6 October 2009
- journal article
- case report
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 39 (11) , 745-750
Abstract
Herein, we report a rare case in which bisphosphonate zoledronic acid (ZA) effectively treated not only multiple bone metastases but also lung, pleural and liver metastases from renal cell carcinoma (RCC). Recently, ZA is used to treat skeletal-related events (SREs) such as bone pain caused by bone metastasis from many kinds of cancer. The patient in the present report had multiple bone metastases from RCC. Remarkable improvement of the bone metastasis was observed following treatment with ZA at a dosage of 4 mg administered once every 4 weeks. Moreover, lung, pleural and liver metastases also diminished markedly in size in response to the treatment. The metastases have shown no progression for 20 months since starting the ZA treatment. We believe that the present report is the first of its kind announcing that ZA monotherapy has been effective for lung, pleural and liver metastases from RCC.Keywords
This publication has 12 references indexed in Scilit:
- Impact of C-Reactive Protein Kinetics on Survival of Patients with Metastatic Renal Cell CarcinomaEuropean Urology, 2009
- Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyThe Lancet Oncology, 2008
- Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no moreExpert Opinion on Biological Therapy, 2008
- Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer PatientsClinical Cancer Research, 2007
- Antitumor Effects of Aminobisphosphonates on Renal Cell Carcinoma Cell LinesJournal of Urology, 2006
- Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancersBJU International, 2005
- The Bisphosphonate YM529 Inhibits Osteolytic and Osteoblastic Changes and CXCR-4–Induced Invasion in Prostate CancerCancer Research, 2005
- Bisphosphonate Therapy for Hormone Refractory Prostate Cancer with Bone MetastasisJournal of Urology, 2003
- The role of osteoclastic activity in prostate cancer skeletal metastasesDrugs of Today, 2002
- Pulmonary resection of metastatic renal cell carcinomaThe Annals of Thoracic Surgery, 1994